# Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

> **NCT02471430** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 17 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Pegylated Interferon-alpha2a

## Key facts

- **NCT ID:** NCT02471430
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2022-08
- **Final completion:** 2023-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471430, "Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02471430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*